# Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

> **NCT03772353** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 59 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib
- **DRUG:** Pyrotinib
- **DRUG:** Letrozole
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03772353
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-12
- **Primary completion:** 2023-06-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772353, "Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03772353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*